Allup Silica Ltd
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 42
- Market Cap
- $7.1M
- Introduction
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimen...
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS
Aptose Biosciences Inc. and the National Cancer Institute (NCI) have entered a Cooperative Research and Development Agreement (CRADA) to collaborate on the clinical development of Aptose’s lead compound tuspetinib (TUS) in NCI’s myeloMATCH trials for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Tuspetinib, an inhibitor of key signaling kinases, will be part of precision medicine trials aiming to develop tailored drug combinations. Aptose is also developing tuspetinib in a triple drug combination (TUS+VEN+AZA) for newly diagnosed AML patients unfit for chemotherapy.
Aptose Biosciences Inc. Announces Pricing Of Public Offering To Raise Approximately $8 Million
Switch market flag for targeted data, right-click for chart options, and use arrows to navigate symbols.
Aptose Reports Results for the Third Quarter 2024
Aptose Biosciences announced financial results for Q3 2024, highlighting a net loss decrease to $7.0 million. The company secured a $10 million loan from Hanmi to support tuspetinib development, showcasing its potential in AML triplet therapies. Aptose faces challenges with Nasdaq compliance, aiming to address stockholders' equity and minimum bid price requirements. Key milestones include initiating TUS+VEN+AZA triplet dosing in newly diagnosed AML patients and reporting data from ongoing studies.
© Copyright 2024. All Rights Reserved by MedPath